Backbone modification of a polypeptide drug alters duration of action in vivo

Nat Biotechnol. 2014 Jul;32(7):653-5. doi: 10.1038/nbt.2920. Epub 2014 Jun 15.

Abstract

Systematic modification of the backbone of bioactive polypeptides through β-amino acid residue incorporation could provide a strategy for generating molecules with improved drug properties, but such alterations can result in lower receptor affinity and potency. Using an agonist of parathyroid hormone receptor-1 (PTHR1), a G protein-coupled receptor in the B-family, we present an approach for α→β residue replacement that enables both high activity and improved pharmacokinetic properties in vivo.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Amino Acid Substitution
  • Amino Acids / chemistry
  • Amino Acids / pharmacokinetics
  • Animals
  • Male
  • Metabolic Clearance Rate
  • Mice, Inbred C57BL
  • Peptide Hormones / blood
  • Peptide Hormones / chemistry*
  • Peptide Hormones / pharmacokinetics*
  • Receptor, Parathyroid Hormone, Type 1 / antagonists & inhibitors*
  • Structure-Activity Relationship
  • Tissue Distribution

Substances

  • Amino Acids
  • PTH1R protein, human
  • Peptide Hormones
  • Receptor, Parathyroid Hormone, Type 1